Chemiluminescence Immunoassay Market

• The global Chemiluminescence Immunoassay Market is experiencing increased product demand for several reasons, with one of the primary factors being the growing occurrence of various chronic diseases and the substantial demand for drug discovery related to these conditions.
• The leading Chemiluminescence Immunoassay Companies working in the market include Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Beckman Coulter, Inc., Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, Maccura Biotechnology Co., DiaSorin, Autobio, Diatron, Daan Gene Co., Ltd, Trivitron Healthcare, Werfen, ALPCO, Medcaptain Medical Technology Co., Ltd., ZECEN Biotech Co., Ltd, PHC Holdings Corporation, Awareness Technology, Inc., Rayto Life and Analytical Sciences Co., Ltd., Shenzhen New Industries Biomedical Engineering Co., Ltd., Guangzhou Jinde Biotech Co., Ltd., and others.

Request for unlocking the CAGR of the "Global Chemiluminescence Immunoassay Market"

Chemiluminescence Immunoassay Market is segmented by Product Type (Instruments, Reagents, And Consumables ), by Application (Hepatitis, Cancer, Covid-19, And Others), by End-User (Hospitals And Diagnostic Labs, Pharmaceutical And Biotech Industries, And Others), and by geography, is estimated to register growth at a remarkable CAGR during the forecast period from 2024-2030 owing to surge in the prevalence of infectious diseases and continuous research and development activities happening in pharmaceutical and biotech industries.

The global chemiluminescence immunoassay analyzers market is estimated to grow at a CAGR of 8.83% during the forecast period from 2024 to 2030. The chemiluminescence immunoassay market is expected to witness growth owing to factors such as the growing prevalence of diseases such as cancer, diabetes, and cardiovascular diseases, among others. Further, the rising awareness of health, especially after the COVID-19 pandemic, and the growing focus on improving the accuracy, portability, affordability, and usability of chemiluminescence immunoassay for end-users are expected to result in appreciable revenue growth in the chemiluminescence immunoassay market during the forecast period (2024-2030).

Chemiluminescence Immunoassay Market Dynamics

One of the noteworthy chemiluminescence immunoassay analyzers market drivers is the increase in cases of diabetes mellitus worldwide. As per the International Diabetes Federation (IDF) 2021, around 537 million adults aged between 20 and 79 years have diabetes worldwide. Various biomarkers associated with diabetes mellitus such as insulin and C-peptide can be detected accurately with chemiluminescence immunoassay thus contributing to its market growth.

The different cancer types affecting millions of people worldwide are another driver for the chemiluminescence immunoassay market. For instance, as per the World Health Organization (WHO) 2022, there were around 2.26 million cases of breast cancer, 2.21 million cases of lung cancer (mainly, non-small cell lung cancer and small cell lung cancer), and 1.93 million cases of colon and rectal cancer, reported in the year 2020 globally. Therefore, the rising awareness of cancer, such as lung, breast, and prostate cancer, amongst the adult population, as well as the recommendation of annual tests for biomarkers of these diseases by doctors is going to accelerate the market for chemiluminescence immunoassay. For instance, many physicians recommend an annual prostate-specific antigen test (PSA) for males aged 50 years or above.

The rise in age-related fertility loss is another driver for the chemiluminescence immunoassay market, as these are widely used for testing fertility and pregnancy. As per the Centers for Disease Control and Prevention (CDC) in 2022, there are around 22% of couples in which women aged 30-39 face problems in having their first child. Also, the continuous research and development across the pharmaceutical and biotechnology industries are driving the growth of the chemiluminescence immunoassay market. However, the availability of alternative products, high cost, and lack of skilled healthcare experts may act as restraining factors to the chemiluminescence immunoassay market growth.

During the period of COVID-19 infection, the market has witnessed a setback owing to the increased number of cases leading to an increased need for diagnostic tools and technologies. The COVID-19 pandemic resulted in vast FDA approvals of diagnostic kits under emergency use status which further led to the development of sensitive and reliable chemiluminescence immunoassay-based diagnostic kits for the SARS-CoV-2 detection. Thus, positively impacting the chemiluminescence immunoassay market.

Chemiluminescence Immunoassay Market Segment Analysis

Chemiluminescence Immunoassay Market is segmented by Product Type (Instruments, Reagents & Consumables), by Application (Hepatitis, Cancer, Covid-19, and Others), by End-User (Hospitals and Diagnostic Labs, Pharmaceutical and Biotech Industries, and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World).

Based on the product type segment of the Chemiluminescence Immunoassay Analyzers Market, Instruments are going to register significant growth in revenue in the chemiluminescence immunoassay market during the forecast period (2024-2030).

This can be ascribed to the rising prevalence of multiple diseases and the application of chemiluminescence immunoassay analyzers in their diagnosis. For instance, EXI 1800, a fully automated chemiluminescence immunoassay analyzer developed by Zybio Inc., can be used in the testing of SARS-CoV-2, diabetes, thyroid, and cardiac diseases, among others. Also, the various advantages associated with the chemiluminescent immunoassay analyzers, such as their simple design, fast analysis, high specificity, excellent sensitivity along with providing reliable results, among others, increase their popularity in various sectors.

Moreover, the various limitations of traditional methods, such as complicated operation, lower efficacy, limited accuracy, high time consumption, and other related drawbacks, can be overcome by chemiluminescence immunoassay analyzers. Therefore, considering the growing demand for this product type, numerous new products are being launched in the market. In July 2020, Sysmex Corporation introduced the Automated Blood Coagulation Analyzers CN-6500/CN-3500 to be used in the field of thrombosis and hemostasis. Therefore, considering the chemiluminescence immunoassay analyzers' advantages and their growing popularity among end-users, this product category is expected to generate considerable revenue, thereby pushing the overall growth of the global chemiluminescence immunoassay market during the forecast period.

North America is expected to dominate the overall Chemiluminescence Immunoassay Market:

Among all the regions, North America is expected to lead the global chemiluminescence immunoassay market. This can be ascribed to the presence of a large patient pool associated with lifestyle diseases, government support, high consumer awareness regarding disease diagnosis, and a highly potent market in terms of product development and launches, among other factors in the region.

One of the prominent factors supporting the growth of North America's chemiluminescence immunoassay analyzers market is the detection of tumor markers indicating cancer development. For instance, according to the National Cancer Institute, it was estimated that around 1.8 million cancer cases were diagnosed in the year 2020 in the United States alone. Also, as per the same source, prostate, lung, and colorectal cancer account for 43% of the total cancer cases in men, and breast, lung, and colorectal cancers make up 50% of total cancer cases in women.

Moreover, the rise in cardiovascular diseases among the U.S. population is another driver of the chemiluminescence immunoassay market growth. For instance, according to the Centers for Disease Control and Prevention (CDC) in 2022, around 18.2 million people aged 20 or above had coronary artery disease in the US. Also, as per the same source, around 805K people face heart attacks every year, with 605K people facing it for the first time, and about 200K having at least one incident of a heart attack before. This indicates the huge need for chemiluminescence immunoassay for the detection of cardiac markers, assisting in cardiovascular disease identification and therefore leading to the chemiluminescence immunoassay market growth.

Also, the rising thyroid diseases prevalence is another major factor in the chemiluminescence immunoassay market growth. According to the American Thyroid Association, in 2019, around 20 million people in America had some form of thyroid disease, and an estimated 12 percent or more of the American population will develop thyroid disease during their lifetime. Therefore, the presence of a large number of patients coupled with the increasing focus of chemiluminescence immunoassay instrument manufacturers on launching new products is expected to bolster the chemiluminescence immunoassay market growth in the United States during the forecast period.

Find out more insights about Chemiluminescence Analysis @ US Chemiluminescence Immunoassay Analyzers Market

Chemiluminescence Immunoassay Companies

Some of the key chemiluminescence immunoassay manufacturers include Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Beckman Coulter, Inc., Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, Maccura Biotechnology Co., DiaSorin, Autobio, Diatron, Daan Gene Co., Ltd, Trivitron Healthcare, Werfen, ALPCO, Medcaptain Medical Technology Co., Ltd., ZECEN Biotech Co., Ltd, PHC Holdings Corporation, Awareness Technology, Inc., Rayto Life and Analytical Sciences Co., Ltd., Shenzhen New Industries Biomedical Engineering Co., Ltd., Guangzhou Jinde Biotech Co., Ltd., and others.

Recent Developmental Activities in the Chemiluminescence Immunoassay Market:

• In November 2021, DiaSorin and MeMed received the CE Mark for Liaison MeMed BV, which is a high-throughput chemiluminescent immunoassay enabling physicians to differentiate between bacterial and viral infections
• In May 2021, Inova Diagnostics Inc. received the FDA approval for its QUANTA Flash® SARS-CoV-2 IgG chemiluminescent immunoassay under emergency use status. 
• In April 2021, Snibe Diagnostic received CE marking for Maglumi HIV Ab/Ag Combi CLIA kit, which detects HIV-1 and HIV-2 antibodies and the HIV-1 p24 antigen.

Key Takeaways from the Chemiluminescence Immunoassay Market Report Study

• Current Chemiluminescence Immunoassay Analyzers Market size (2024), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on the chemiluminescence immunoassay market is significant. To capture and analyze suitable indicators, our experts are closely watching the market.
• The top key chemiluminescence immunoassay product/services/technology developments, mergers, acquisitions, partnerships, joint ventures happened over the  last 3 years.
• Key chemiluminescence immunoassay companies dominating the global chemiluminescence immunoassay market.
• Various opportunities available for competitors in the chemiluminescence immunoassay market space.
• What are the top-performing chemiluminescence immunoassay segments in 2024? How will these segments perform in 2030?
• Which are the top-performing chemiluminescence immunoassay regions and countries in the current market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for chemiluminescence immunoassay market growth in the future?

Target Audience that can benefit from this Chemiluminescence Immunoassay Market Report Study

• Chemiluminescence immunoassay products manufacturers
• Research organizations and consulting companies
• Chemiluminescence immunoassay-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Chemiluminescence Immunoassay Analyzers Distributors and Traders
• Various end users who want to know more about the chemiluminescence immunoassay market and the latest technological developments in the chemiluminescence immunoassay market.

Stay Updated with us @ New DelveInsight Blogs